Last reviewed · How we verify
Intrastromal voriconazole
Intrastromal voriconazole is an antifungal agent delivered directly into the corneal stroma to treat fungal keratitis by inhibiting fungal cell wall synthesis.
Intrastromal voriconazole is an antifungal agent delivered directly into the corneal stroma to treat fungal keratitis by inhibiting fungal cell wall synthesis. Used for Fungal keratitis (corneal fungal infection).
At a glance
| Generic name | Intrastromal voriconazole |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Voriconazole is a triazole antifungal that inhibits lanosterol 14α-demethylase, a key enzyme in fungal ergosterol synthesis, disrupting the fungal cell membrane. When administered intrastromally (directly into corneal tissue), it achieves high local concentrations to treat corneal fungal infections that are difficult to penetrate with topical or systemic administration.
Approved indications
- Fungal keratitis (corneal fungal infection)
Common side effects
- Corneal inflammation
- Anterior chamber reaction
- Corneal edema
- Pain or discomfort at injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intrastromal voriconazole CI brief — competitive landscape report
- Intrastromal voriconazole updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI